Topical Analgesics: Capsaicin, Lidocaine and Topical NSAIDs

Mechanism of action

Each class acts via a distinct mechanism, and that is why the choice is not interchangeable. Capsaicin is an agonist at the TRPV1 receptor on nociceptive C fibers in the skin — initial activation produces an intense burning sensation and substance P release; repeated use leads to substance P depletion and local desensitization, with reduction of nociceptive signaling after days to weeks. It is a "controlled exhaustion" of the C fiber.

Lidocaine blocks voltage-gated sodium channels in peripheral nerve terminals, reducing spontaneous ectopic firing characteristic of neuropathic pain. This profile makes it particularly useful in postherpetic neuralgia and in focal peripheral neuropathic pain — with an analgesic effect that does not depend on deep penetration.

Topical NSAIDs inhibit cyclooxygenases in the dermis and in immediately underlying tissues (superficial joints such as the hand, knee, elbow), reducing local prostaglandins and therefore the sensitization of peripheral nociceptors. The systemic absorption is 5-15% of the oral route at equivalent doses — preserving local efficacy and attenuating the gastrointestinal, cardiovascular and renal risk characteristic of the class.

Scientific evidence

Topical analgesics have moved beyond being merely a marginal alternative and now appear in guidelines for neuropathic pain and osteoarthritis as a legitimate option, especially in patients for whom the oral route is undesirable.

The Cochrane reviews of Derry et al. (2017) on 8% capsaicin in chronic neuropathy consolidated the patch as an option with moderate efficacy and prolonged effect (up to 12 weeks per application) in postherpetic neuralgia and in peripheral diabetic neuropathy. The NNT around 7-10 for ≥30% pain reduction is clinically relevant in a population that is often refractory. For low-dose capsaicin cream, the effect is smaller and adherence is the major limitation.

The Cochrane review of Derry et al. (2016) on topical NSAIDs in acute musculoskeletal pain and in hand and knee OA shows NNT ~6 for significant pain reduction in OA, with consistent evidence for topical diclofenac. The article on oral NSAIDs contextualizes why current guidelines (NICE 2022, OARSI 2019) prefer topical over oral in superficial OA.

In neuropathic pain, the Finnerup et al. (Lancet Neurology 2015) guideline positions 8% capsaicin and 5% lidocaine as second-line options in localized peripheral neuropathic pain (first line: duloxetine, pregabalin, gabapentin, amitriptyline). The NICE CG173 maintains a similar recommendation, with capsaicin in selected scenarios. Specific studies by Simon et al. documented efficacy of the lidocaine patch in postherpetic neuralgia, where it is a particularly useful option given the safety profile in older adults.

Indications

The best use of topicals is for localized pain — focal neuropathic or superficial musculoskeletal — and especially in patients for whom the oral route is contraindicated or carries increased risks.

How they are used

Dosing depends on the class. Capsaicin in low-dose cream (0.025-0.075%) requires 3-4 daily applications for weeks — adherence is the largest obstacle owing to initial burning. The 8% capsaicin patch is a single application in a professional setting (30-60 minutes, with local anesthesia) with relief of up to 12 weeks — but its availability varies by country. Lidocaine 5% patch (Lidoderm) follows a 12h on / 12h off schedule with response within days. Topical NSAIDs (diclofenac, ketoprofen) are applied 3-4×/day, with assessment at 2-4 weeks.

Topical NSAID applied to a knee with OA: high local concentration with systemic absorption at 5-15% of oral levels

Fig. · placeholder

Topical analgesics by generic name

Availability is heterogeneous across countries. Topical NSAIDs (diclofenac, ketoprofen) have a consolidated market and generic versions; lidocaine 5% patch requires a prescription and has a higher price; 8% capsaicin patch is approved in the US (Qutenza) but availability varies elsewhere. Public health systems rarely supply topicals as a rule — private insurance covers partially depending on the plan.

Topical diclofenac is over-the-counter (no prescription required) in many countries. Lidocaine patch requires a medical prescription. 8% capsaicin patch availability varies by country (the only route of access is importation in selected centers). One practical alert: many popular products combine camphor, menthol and salicylate — the individual evidence for each component is modest and that of the combination is even less studied. In guideline terms, we prefer the specific evidence-based topical drug.

Dosing, interactions and special populations

Older adults. Topicals are frequently the preferred option when oral therapy has a contraindication (GI, CV, renal risk). In knee and hand OA, the topical NSAID appears as first line in recent guidelines precisely for that reason. In postherpetic neuralgia, lidocaine 5% patch has an especially favorable profile in older adults.

Pregnancy. Topical NSAIDs over a small área are a safer option than oral given the limited systemic absorption, but still avoided in the 3rd trimester. Topical lidocaine is generally accepted for occasional use. 8% capsaicin patch is avoided in pregnancy due to lack of data. Decision case by case with the obstetrician.

Lactating mothers. Topical NSAID over an área distant from the nipple is generally acceptable for occasional use. Topical lidocaine in a localized área is compatible. 8% capsaicin is avoided owing to the limitation of data.

Children. Few products with validated pediatric indication; use is individualized by the physician, with preference for non-pharmacological approaches whenever possible.

Risks and contraindications

The safety profile of topicals is consistently more favorable than that of equivalent systemic routes — but it is not zero. Most adverse events are local and reversible.

Limitations and what is still not known

Topical analgesics have gained well-deserved ground, but there are two common errors in opposite directions: treating them as "risk-free" because they are topical, or ignoring them out of a bias against efficacy. The correct reading is in the middle — they are useful tools with specific indications and recognizable limitations.

Evidence Gaps

Combination formulations. Popular synergistic products (menthol + camphor + salicylate) have weak evidence compared with specific drugs — the combination of components is rarely justified by well-conducted comparative studies, and most of those launches rely on tolerance data and historical use, not on recent controlled trials.

Cost and availability. The lidocaine 5% patch can be expensive; the 8% capsaicin patch is not available in all countries. Out of pocket, cost can be a real barrier — especially in retired older adults. International guidelines position the topical as first line in specific scenarios without always considering this access dimension.

Non-neuropathic and non-OA chronic pain. Scarce evidence in chronic low back pain, fibromyalgia and diffuse myofascial pain. In those conditions, topical use is frequent in practice, but based on extrapolation and patient preference more than on robust data.

Relationship with medical acupuncture

The compatibility between topical analgesics and medical acupuncture is favorable — no pharmacological interactions have been described in the available literature. Acupuncture can contribute to lower need for topicals in myofascial pain and in chronic pain with a central component, and topicals can complement acupuncture in localized persistent pain — for example, knee OA in a multimodal plan that includes multimodal treatment with physical therapy, acupuncture and topical NSAID during a flare. Medication adjustments remain a decision of the attending physician.

When to seek medical care

Topicals are part of responsible self-medication in many cases (over-the-counter diclofenac, for example), but there are clear signs that call for medical evaluation.